Intelligent Bio Launches Clinical Trial for Fingerprint-Based Codeine Detection Technology

Intelligent Bio initiated a clinical study on June 16, 2026, to evaluate fingerprint drug screening technology for codeine detection. The non-invasive testing method represents the company's effort to develop alternative drug screening solutions beyond traditional blood or urine analysis. The study marks a regulatory development step for the biotech firm's fingerprint-based detection platform. Codeine, a prescription opioid, is commonly monitored in clinical and workplace drug testing programs. No details on trial size, duration, or FDA pathway were disclosed in the initial announcement. Financial terms and stock performance data were not provided. The company's ticker symbol was not specified in available filings.